• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Laser-ac­ti­vat­ed eye can­cer drug de­vel­op­er Au­ra Bio­sciences scores $40M in Medicxi-led round

7 years ago
Financing

Does an im­proved safe­ty pro­file strength­en Al­ler­gan's case for a wet AMD chal­lenge to Lu­cen­tis?

7 years ago
R&D

Sang­amo bounces back with up­beat snap­shot on hem A al­lied with Pfiz­er and a plan to beef up AAV man­u­fac­tur­ing

7 years ago
R&D

The top 20 pre­clin­i­cal biotech deals ranked by cash up­front re­veals 3 big play­ers — and some ma­jor league stinkers

7 years ago
Deals
Discovery

Evoke's sole treat­ment fails to evoke the FDA's con­fi­dence, as agency re­jects Gi­moti af­ter flag­ging con­cerns last ...

7 years ago
R&D

Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

7 years ago
R&D
Biotech Voices

At­las wraps Arteaus sto­ry with $260M roy­al­ty sale as Em­gal­i­ty sales inch­es up­ward

7 years ago
Pharma

Mer­ck­'s Keytru­da wins first check­point in­hibitor lung can­cer ap­proval in Chi­na; Puma sells rights to Ner­l­ynx in ...

7 years ago
News Briefing

AACR roundup: Check­point cock­tails score ear­ly suc­cess­es as Roche's triple shows high re­sponse rate in front­line ...

7 years ago
R&D

AACR: Bay Area biotech bets on an­ti­bod­ies armed with im­muno-stim­u­lant to fight check­point-re­sis­tant can­cers

7 years ago
Discovery

Cam­bridge fund rais­es more than $196M in the UK's hefti­est 2019 fund­ing round

7 years ago
Financing

Pfiz­er biotech spin­out nabs $125M megaround as Bain-backed syn­di­cate bets on its late-stage game plan

7 years ago
Financing
Startups

AACR: Lit­tle Apex­i­gen steals the show with their CD40/Op­di­vo cock­tail as AACR gets un­der­way

7 years ago
R&D

No­var­tis just signed a $1.6B buy­out pact with a lead play­er in an emerg­ing an­ti-in­flam­ma­to­ry field

7 years ago
Deals

Still hunt­ing a block­buster, Mer­ck KGaA scores a win in the FDA ap­proval col­umn — more than 13 years in the mak­ing

7 years ago
Pharma

Af­ter gain­ing key sup­port for Cel­gene buy­out, Bris­tol-My­ers CEO Caforio emerges as like­ly win­ner in loom­ing ...

7 years ago
Deals

BIO tells SEC: do away with quar­ter­ly re­ports for small biotechs

7 years ago
Pharma

Rare dis­ease gene ther­a­py gains Prime sta­tus; FDA ap­proves first drug for in­flam­ma­to­ry arthri­tis nr-axS­pA

7 years ago
News Briefing

Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

7 years ago
Pharma
Cell/Gene Tx

Cel­gene shares jump as Bris­tol-My­ers gains key sup­port from proxy ad­vis­er for loom­ing buy­out vote

7 years ago
Deals

Blue­bird's one-shot gene ther­a­py for be­ta tha­lassemia of­fi­cial­ly se­cures EMA back­ing — ap­proval ex­pect­ed in the ...

7 years ago
Pharma
Cell/Gene Tx

Sunao Man­abe takes top job at Dai­ichi Sankyo in wake of As­traZeneca deal; CAR-T play­er Celyad pro­motes Fil­ip­po Pet­ti ...

7 years ago
Peer Review

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

7 years ago
Pharma

Durable, safe and ef­fec­tive long-term kid­ney drug da­ta from Tri­ci­da fu­el block­buster po­ten­tial

7 years ago
R&D
First page Previous page 946947948949950951952 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.